Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
J Neurochem. 2019 Jan;148(2):252-274. doi: 10.1111/jnc.14627. Epub 2018 Dec 21.
Painful peripheral neuropathy is a severe and difficult-to-treat neurological complication associated with cancer chemotherapy. Although chemotherapeutic drugs such as paclitaxel are known to cause tonic activation of presynaptic NMDA receptors (NMDARs) to potentiate nociceptive input, the molecular mechanism involved in this effect is unclear. α2δ-1, commonly known as a voltage-activated calcium channel subunit, is a newly discovered NMDAR-interacting protein and plays a critical role in NMDAR-mediated synaptic plasticity. Here we show that paclitaxel treatment in rats increases the α2δ-1 expression level in the dorsal root ganglion and spinal cord and the mRNA levels of GluN1, GluN2A, and GluN2B in the spinal cord. Paclitaxel treatment also potentiates the α2δ-1-NMDAR interaction and synaptic trafficking in the spinal cord. Strikingly, inhibiting α2δ-1 trafficking with pregabalin, disrupting the α2δ-1-NMDAR interaction with an α2δ-1 C-terminus-interfering peptide, or α2δ-1 genetic ablation fully reverses paclitaxel treatment-induced presynaptic NMDAR-mediated glutamate release from primary afferent terminals to spinal dorsal horn neurons. In addition, intrathecal injection of pregabalin or α2δ-1 C-terminus-interfering peptide and α2δ-1 knockout in mice markedly attenuate paclitaxel-induced pain hypersensitivity. Our findings indicate that α2δ-1 is required for paclitaxel-induced tonic activation of presynaptic NMDARs at the spinal cord level. Targeting α2δ-1-bound NMDARs, not the physiological α2δ-1-free NMDARs, may be a new strategy for treating chemotherapy-induced neuropathic pain. OPEN SCIENCE BADGES: This article has received a badge for Open Materials because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
痛性周围神经病是一种严重且难以治疗的与癌症化疗相关的神经并发症。虽然紫杉醇等化疗药物已知会引起突触前 NMDA 受体(NMDAR)的紧张性激活,从而增强伤害性传入,但这种作用的分子机制尚不清楚。α2δ-1,通常称为电压激活钙通道亚基,是一种新发现的 NMDAR 相互作用蛋白,在 NMDAR 介导的突触可塑性中发挥关键作用。在这里,我们发现在大鼠中紫杉醇处理会增加背根神经节和脊髓中的 α2δ-1 表达水平,以及脊髓中的 GluN1、GluN2A 和 GluN2B 的 mRNA 水平。紫杉醇处理还增强了脊髓中 α2δ-1-NMDAR 相互作用和突触转运。引人注目的是,用普瑞巴林抑制 α2δ-1 转运,用 α2δ-1 C 端干扰肽破坏 α2δ-1-NMDAR 相互作用,或 α2δ-1 基因缺失完全逆转紫杉醇处理诱导的初级传入末梢到脊髓背角神经元的突触前 NMDAR 介导的谷氨酸释放。此外,鞘内注射普瑞巴林或 α2δ-1 C 端干扰肽和 α2δ-1 基因敲除可显著减轻紫杉醇引起的痛觉过敏。我们的研究结果表明,α2δ-1 是紫杉醇在脊髓水平引起突触前 NMDAR 紧张性激活所必需的。靶向 α2δ-1 结合的 NMDAR,而不是生理性的 α2δ-1 游离 NMDAR,可能是治疗化疗引起的神经性疼痛的一种新策略。开放科学徽章:本文因提供了重现论文中研究的所有相关信息而获得了“开放材料”徽章。本文的完整开放科学披露表格可在文章末尾找到。有关开放实践徽章的更多信息,请访问 https://cos.io/our-services/open-science-badges/。